Medtronic plc. has recently presented new data at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, showcasing the success of the MiniMed™ 780G system in helping individuals with type 1 diabetes surpass international targets for time in range (TIR). The data revealed that with the use of recommended optimal settings, over 100,000 real-world users achieved a TIR of 78%, outperforming the international goal of 70% TIR.
Additionally, the study introduced a new metric called Time in Tight Range (TITR), which aims to measure the percentage of time individuals spend in the tighter glucose range of 70-140 mg/dL. The MiniMed™ 780G system users achieved a TITR of over 56% when utilizing the recommended optimal settings, demonstrating the system’s ability to bring users closer to normal blood sugar levels.
Furthermore, the system has shown promising results in the United States, with early real-world users achieving over 80% TIR. Closed loop exits occurred less than once per week on average, showcasing the system’s reliability and effectiveness in managing blood sugar levels. The latest system enhancements have led to high satisfaction rates and improved quality of life benefits for users.
Dr. James ThrasherMD, Founder of Arkansas Diabetes and Endocrinology Center, emphasized that optimizing the MiniMed™ 780G system with recommended settings can greatly exceed the ADA recommended goal of 70% TIR. Dr. Thrasher highlighted the transformative impact of automated insulin delivery (AID) systems in diabetes care and the importance of selecting systems with powerful algorithms.
The MiniMed™ 780G system’s success in helping individuals achieve TIR and TITR goals reflects a significant advancement in diabetes management. By leveraging continuous glucose monitoring technology, the system is empowering users to maintain optimal blood sugar levels while minimizing hypoglycemia. With a focus on innovation and customer experience, Medtronic Diabetes is committed to designing the future of diabetes management through cutting-edge technology and always-on support.
For more information on Medtronic and the MiniMed™ 780G system, visit their website at http://www.medtronicdiabetes.com. Join Medtronic in their mission to alleviate the burden of diabetes and empower individuals to live life on their terms with advanced diabetes technology.
Source link
